WallStreetZenWallStreetZen

NASDAQ: SCPH
Scpharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for SCPH

Based on 1 analyst offering 12 month price targets for Scpharmaceuticals Inc.
Min Forecast
$18.00+307.24%
Avg Forecast
$18.00+307.24%
Max Forecast
$18.00+307.24%

Should I buy or sell SCPH stock?

Based on 1 analyst offering ratings for Scpharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SCPH stock forecasts and price targets.

SCPH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-15

1 of 1

Forecast return on equity

Is SCPH forecast to generate an efficient return?
Company
374.25%
Industry
71.74%
Market
80.3%
SCPH's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SCPH forecast to generate an efficient return on assets?
Company
117.19%
Industry
30.97%
SCPH is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SCPH earnings per share forecast

What is SCPH's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$1.46
Avg 2 year Forecast
-$0.80
Avg 3 year Forecast
$0.47

SCPH revenue forecast

What is SCPH's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$39.5M+124.23%
Avg 2 year Forecast
$100.6M+470.7%
Avg 3 year Forecast
$185.0M+949.42%
SCPH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SCPH revenue growth forecast

How is SCPH forecast to perform vs Biotechnology companies and vs the US market?
Company
117.39%
Industry
64.4%
Market
11.24%
SCPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SCPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SCPH vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SCPH$4.42$18.00+307.24%Buy
ACHV$4.63$14.00+202.38%Strong Buy
CNTX$2.12$6.50+206.60%Strong Buy
INMB$8.08N/AN/A
CGEN$1.82$4.00+119.78%Strong Buy

Scpharmaceuticals Stock Forecast FAQ

Is Scpharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SCPH) stock is to Buy SCPH stock.

Out of 1 analyst, 0 (0%) are recommending SCPH as a Strong Buy, 1 (100%) are recommending SCPH as a Buy, 0 (0%) are recommending SCPH as a Hold, 0 (0%) are recommending SCPH as a Sell, and 0 (0%) are recommending SCPH as a Strong Sell.

If you're new to stock investing, here's how to buy Scpharmaceuticals stock.

What is SCPH's earnings growth forecast for 2024-2026?

(NASDAQ: SCPH) Scpharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.64%.

Scpharmaceuticals's earnings in 2024 is -$57,708,000.On average, 4 Wall Street analysts forecast SCPH's earnings for 2024 to be -$52,549,301, with the lowest SCPH earnings forecast at -$56,965,966, and the highest SCPH earnings forecast at -$45,068,011. On average, 4 Wall Street analysts forecast SCPH's earnings for 2025 to be -$28,753,391, with the lowest SCPH earnings forecast at -$40,020,394, and the highest SCPH earnings forecast at -$16,224,484.

In 2026, SCPH is forecast to generate $16,945,572 in earnings, with the lowest earnings forecast at -$1,442,176 and the highest earnings forecast at $28,843,527.

What is SCPH's revenue growth forecast for 2024-2026?

(NASDAQ: SCPH) Scpharmaceuticals's forecast annual revenue growth rate of 117.39% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.24%.

Scpharmaceuticals's revenue in 2024 is $17,632,000.On average, 3 Wall Street analysts forecast SCPH's revenue for 2024 to be $1,425,447,114, with the lowest SCPH revenue forecast at $1,330,768,236, and the highest SCPH revenue forecast at $1,539,523,264. On average, 3 Wall Street analysts forecast SCPH's revenue for 2025 to be $3,628,010,960, with the lowest SCPH revenue forecast at $2,833,516,003, and the highest SCPH revenue forecast at $4,539,250,093.

In 2026, SCPH is forecast to generate $6,671,255,460 in revenue, with the lowest revenue forecast at $5,302,161,388 and the highest revenue forecast at $8,894,622,700.

What is SCPH's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: SCPH) forecast ROA is 117.19%, which is higher than the forecast US Biotechnology industry average of 30.97%.

What is SCPH's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SCPH price target, the average SCPH price target is $18.00, with the highest SCPH stock price forecast at $18.00 and the lowest SCPH stock price forecast at $18.00.

The Wall Street analyst predicted that Scpharmaceuticals's share price could reach $18.00 by May 15, 2025. The average Scpharmaceuticals stock price prediction forecasts a potential upside of 307.24% from the current SCPH share price of $4.42.

What is SCPH's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: SCPH) Scpharmaceuticals's current Earnings Per Share (EPS) is -$1.48. On average, analysts forecast that SCPH's EPS will be -$1.46 for 2024, with the lowest EPS forecast at -$1.58, and the highest EPS forecast at -$1.25. On average, analysts forecast that SCPH's EPS will be -$0.80 for 2025, with the lowest EPS forecast at -$1.11, and the highest EPS forecast at -$0.45. In 2026, SCPH's EPS is forecast to hit $0.47 (min: -$0.04, max: $0.80).

What is SCPH's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: SCPH) forecast ROE is 374.25%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.